|
Primary gastric non-Hodgkin's lymphoma: clinical features,
management, and prognosis of 185 patients with diffuse large
B-cell lymphoma.Ann
Oncol. 1999 Dec;10(12):1441-9.
BACKGROUND:
Primary gastric non-Hodgkin's lymphoma (PG-NHL) is common in Saudi
Arabia. This has prompted the analysis of a large series of
patients with PG-NHL having high-grade diffuse large B-cell
lymphoma (DLCL) in order to define the clinical features and
outcome of this disease. PATIENTS AND METHODS: The data of all
adult patients in the series with PG-NHL having DLCL histology
were retrospectively reviewed. Patients were eligible if they had
biopsy-confirmed diagnoses obtained by endoscopy or following
laparotomy. RESULTS: Over a 16-year period, 185 patients with DLCL
PG-NHL were identified and their data were reviewed. Patients had
a median age of 54 years. In 53% of them only one initial
therapeutic modality was given, while 47% were managed by a
multi-modality approach. One hundred forty patients (76%), 19
(10%), and 26 (14%) attained complete remission (CR), partial
remission, and no response/progressive disease, respectively.
Multivariate analysis showed that poor performance status and
advanced stage were negatively associated with the likelihood of
attaining CR. Over a median follow-up of 54 months, 118 (64%) of
the patients were alive and disease-free, 17 (9%) were alive with
evidence of disease, and the remaining 50 (27%) were dead. The
projected 5-year and 10-year overall survivals (OS) (+/- SD) were
68% (+/- 4%) and 61% (+/- 6%), respectively. The Cox proportional
hazards model identified the same variables of response as adverse
prognostic factors of survival. Using the influence of performance
status, and stage, a prognostic index was constructed to recognize
three prognostically distinctive risk categories with overall
survival proportions of 87%, 61%, and 45%, respectively. The
unadjusted International Prognostic Index, however, failed to
classify patients into prognostically meaningful risk strata. Of
the 140 patients who achieved CR, the median disease-free survival
(DFS) was not reached, but the predicted 5- and 10-year DFS were
82% and 75%, respectively. A multivariate analysis identified poor
performance status as the only independent prognostic covariate
that adversely influenced DFS. Our analysis showed that compared
with single-modality management, multi-modality strategy attained
significantly higher CR, and advantageous OS and DFS. CONCLUSIONS:
This large series characterized the clinico-pathologic features
and outcome of patients with DLCL PG-NHL. Performance status, and
stage significantly influenced patient outcome. A prognostic index
was developed and it identified three prognostically distinctive
risk groups; however, prospective validation is warranted. |